


PHARMACEUTICAL 2022



Carisma Therapeutics Inc. Rank 157 of 466





PHARMACEUTICAL 2022

sesen

Carisma Therapeutics Inc. Rank 157 of 466

The relative strengths and weaknesses of Carisma Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Carisma Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Carisma Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 190%, being 113% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	205,605
Cost of Goods Sold	0
Intangible Assets	27,764
Liabilities, Current	11,568
Liabilities, Non-Current	57,469
Other Assets	7,335
Other Compr. Net Income	0
Other Expenses	-27,885
Other Liabilities	0
Other Net Income	-60
Other Revenues	26,544
Property and Equipment	43
Research and Development	25,312
Selling, General and Administrative Expense	29,393

Output Variable	Value in 1000 USD
Assets	240,747
Liabilities	69,037
Expenses	26,820
Revenues	26,544
Stockholders Equity	171,710
Net Income	-336
Comprehensive Net Income	-336
Economic Capital Ratio	190%

